Stay updated with breaking news from Breast Unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.
Bolton is being lit up pink this month to mark the significance of Breast Cancer Awareness month
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that new data was presented at the European Society of Breast Imaging ("EUSOBI") Scientific Meeting in Valencia, Spain by Lucía Graña-López, MD, PhD, principal investigator of the independent, non-sponsored study.
Growing body of evidence-based data is giving women a minimally invasive alternative to the standard of care lumpectomyPatients throughout the European Union have access to ProSense for the...
Royal Bolton Hospital has been named one of the UK’s first ‘Centres of Excellence’ for care.